Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 9/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | HTR2B | P41595 | 4/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27183518 | 0.89 | PNMT (0.47) | PNMTADRA2AADRA2BADRA2CHTR2C | |
| SCHEMBL25257916 | 0.85 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2CHTR2C | |
| SCHEMBL25259990 | 0.82 | PNMT (0.37) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| SCHEMBL30068989 | 0.82 | PNMT (0.37) | PNMTHTR2CHTR2AHTR2BASIC3 | |
| SCHEMBL31013896 | 0.81 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2CHTR2C | |
| SCHEMBL15503053 | 0.81 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2CHTR2C | |
| SCHEMBL15503117 | 0.78 | PNMT (0.44) | PNMTADRA2AADRA2BADRA2CHTR2C | |
| SCHEMBL19711552 | 0.78 | PNMT (0.53) | PNMTADRA2AADRA2BADRA2CHTR2C | |
| SCHEMBL19684576 | 0.78 | PNMT (0.53) | PNMTADRA2AADRA2BADRA2CHTR2C | |
| SCHEMBL2427972 | 0.75 | HTR2C (0.49) | PNMTADRA2AADRA2BADRA2CHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4596544-A1 | EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Miracure Biotechnology Limited (CN) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025108411-A1 | EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京沐华生物科技有限责任公司 | 2025-05-30 | — | — | WO | disclosed |
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2024-06-06 | — | — | US | disclosed |
| CN-117843618-A | EP300/CBP regulator and preparation method and application thereof | 北京沐华生物科技有限责任公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20240109868-A1 | EP300/CBP MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Miracure Biotechnology Limited (CN) | 2024-04-04 | — | — | US | disclosed |
| WO-2024046504-A1 | EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京沐华生物科技有限责任公司 | 2024-03-07 | — | — | WO | disclosed |
| EP-4303216-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-01-10 | — | — | EP | disclosed |
| CN-116981661-A | Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| WO-2022184152-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109868-A1 | EP300/CBP MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | EP300, CREBBP, BPTF | PNMT 2277/4885ADRA2A 3321/4885ADRA2B 2851/4885 |
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, HASPIN | PNMT 4428/4885ADRA2A 4279/4885ADRA2B 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.